---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-069658"
form_type: "8-K"
ticker: "COCH"
cik: "0001840877"
company_name: "Envoy Medical, Inc."
filed_at: "2025-07-31T23:59:59+00:00"
generated_at: "2026-05-17T22:27:28.130534+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Envoy Medical reports Q2 clinical progress, cash $5.3M; CPT codes for Esteem device effective July 1

## Summary
- All 10 Acclaim cochlear implant trial participants activated; no serious adverse events at one-month follow-up.
- Five CPT codes for totally implantable active middle ear implants (Esteem) approved by AMA, effective July 1, 2025.
- R&D expenses decreased to $2.485M from $2.6M; G&A increased $0.5M due to severance accrual.
- Cash balance $5.3M as of June 30, 2025; net revenues increased by $10K YoY.
- Subsequent to quarter end, two US and three Australian patents issued to strengthen IP portfolio.

## SEC filing metadata
- accession: 0001213900-25-069658
- form_type: 8-K
- ticker: COCH
- cik: 0001840877
- company_name: Envoy Medical, Inc.
- filed_at: 2025-07-31T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840877/000121390025069658/0001213900-25-069658-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840877/000121390025069658/ea0250901-8k_envoy.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-069658
- JSON: https://secwatch.observer/filing/0001213900-25-069658.json
- Plain text: https://secwatch.observer/filing/0001213900-25-069658.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.